{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:19:54Z","timestamp":1787019594517,"version":"build-2736575974"},"reference-count":30,"publisher":"American Society of Hematology","issue":"24","license":[{"start":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T00:00:00Z","timestamp":1728086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,24]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Febrile neutropenia (FN) is the most common reason for hospital readmission after chemotherapy for acute myeloid leukemia (AML) and is a major driver of health care resource utilization. Although FN risk models exist, they have largely been developed and validated for solid tumors. We therefore examined whether baseline characteristics could predict which patients with AML and FN have a lower risk of progression to severe illness. We identified adults with high-grade myeloid neoplasms (\u226510% blasts in the blood\/marrow) who received intensive chemotherapy and who were admitted for FN between 2016 and 2023. We collected baseline clinical and disease variables. Outcomes were: infections identified, hospital length of stay (LOS), intensive care unit (ICU) admission, and survival. A lower-risk (LR) outcome was defined as LOS &amp;lt;72 hours without ICU admission or inpatient death. Univariate and multivariable (MV) logistic regression models were used to assess covariate associations with outcomes. We identified 397 FN admissions in 248 patients (median age, 61; [range, 29-77] years). The median hospital LOS was 6\u00a0days (range, 1-56) days; 10% required ICU admission, and 3.5% died inpatient. Only 15% of admissions were LR. Infection was identified in 59% of admissions. Physiologic parameters, including heart rate, blood pressure, and fever height, were the best predictors of LR admission and infection. We developed MV models to predict LR admission and infection with area under the curve (AUC) of 0.82 and 0.72, respectively. Established FN and critical illness models were not predictive of outcomes in AML, and we could not identify a LR group; thus, an AML-specific FN risk model requires further development and validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014291","type":"journal-article","created":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T19:58:40Z","timestamp":1728158320000},"page":"6161-6170","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Identification of factors predicting low-risk febrile neutropenia admissions in adults with acute myeloid leukemia"],"prefix":"10.1182","volume":"8","author":[{"given":"Khushboo V.","family":"Pal","sequence":"first","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Othus","sequence":"additional","affiliation":[{"name":"2Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Ali","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2503-4207","authenticated-orcid":false,"given":"Katherine","family":"Russell","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Shaw","sequence":"additional","affiliation":[{"name":"3Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary-Elizabeth M.","family":"Percival","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"},{"name":"3Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1902-5972","authenticated-orcid":false,"given":"Paul C.","family":"Hendrie","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4362-7773","authenticated-orcid":false,"given":"Jacob S.","family":"Appelbaum","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"},{"name":"3Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9268-3341","authenticated-orcid":false,"given":"Roland B.","family":"Walter","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"},{"name":"4Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"5Department of Laboratory Medicine & Pathology, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna B.","family":"Halpern","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"},{"name":"3Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,12,11]]},"reference":[{"issue":"10","key":"2024122319504098700_bib1","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.21847","article-title":"Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients","volume":"106","author":"Kuderer","year":"2006","journal-title":"Cancer"},{"issue":"3","key":"2024122319504098700_bib2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/10428190701809172","article-title":"Neutropenic fever and severe sepsis in adult acute myeloid leukemia (AML) patients receiving intensive chemotherapy: causes and consequences","volume":"49","author":"H\u00e4m\u00e4l\u00e4inen","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"23","key":"2024122319504098700_bib3","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1182\/blood.V126.23.2089.2089","article-title":"Cost of hospitalization in patients with cancer and febrile neutropenia and impact of comorbid conditions","volume":"126","author":"Lyman","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2024122319504098700_bib4","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1182\/asheducation-2013.1.414","article-title":"Evidence-based approach to treatment of febrile neutropenia in hematologic malignancies","volume":"2013","author":"Gea-Banacloche","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"3","key":"2024122319504098700_bib5","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1002\/1097-0142(197703)39:3<1345::AID-CNCR2820390350>3.0.CO;2-R","article-title":"Fever, neutropenia and malignancy: a clinical syndrome in evolution","volume":"39","author":"Pennington","year":"1977","journal-title":"Cancer"},{"issue":"11","key":"2024122319504098700_bib6","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1200\/OP.21.00148","article-title":"Risk-stratifying treatment strategies for febrile neutropenia-tools, tools everywhere, and not a single one that works?","volume":"17","author":"Wijeratne","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"2","key":"2024122319504098700_bib7","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1200\/JCO.1992.10.2.316","article-title":"Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule","volume":"10","author":"Talcott","year":"1992","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024122319504098700_bib8","doi-asserted-by":"crossref","first-page":"101248","DOI":"10.1016\/j.beha.2021.101248","article-title":"Perspectives on current survival and new developments in AML","volume":"34","author":"Rowe","year":"2021","journal-title":"Best Pract Res Clin Haematol"},{"issue":"16","key":"2024122319504098700_bib9","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1200\/JCO.2000.18.16.3038","article-title":"The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients","volume":"18","author":"Klastersky","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2024122319504098700_bib10","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1200\/JCO.2014.57.2347","article-title":"Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the clinical index of stable febrile neutropenia in a prospective cohort of patients from the FINITE study","volume":"33","author":"Carmona-Bayonas","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024122319504098700_bib11","doi-asserted-by":"crossref","first-page":"9048","DOI":"10.1038\/s41598-021-88207-6","article-title":"Usefulness analysis of the 2018 ASCO\/IDSA guideline for outpatient management of fever and neutropenia in adults treated for malignancy","volume":"11","author":"Hwang","year":"2021","journal-title":"Sci Rep"},{"issue":"7","key":"2024122319504098700_bib12","doi-asserted-by":"crossref","first-page":"882","DOI":"10.6004\/jnccn.2016.0093","article-title":"Prevention and treatment of cancer-related infections, version 2.2016, NCCN clinical practice guidelines in oncology","volume":"14","author":"Baden","year":"2016","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"2","key":"2024122319504098700_bib13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/leu.2013.176","article-title":"Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD Anderson","volume":"28","author":"Othus","year":"2014","journal-title":"Leukemia"},{"issue":"2","key":"2024122319504098700_bib14","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41375-019-0586-6","article-title":"Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm","volume":"34","author":"Halpern","year":"2020","journal-title":"Leukemia"},{"issue":"2","key":"2024122319504098700_bib15","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/MOH.0000000000000481","article-title":"Outpatient induction and consolidation care strategies in acute myeloid leukemia","volume":"26","author":"Halpern","year":"2019","journal-title":"Curr Opin Hematol"},{"issue":"4","key":"2024122319504098700_bib16","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1200\/JOP.18.00016","article-title":"Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America clinical practice guideline update summary","volume":"14","author":"Taplitz","year":"2018","journal-title":"J\u00a0Oncol Pract"},{"issue":"11","key":"2024122319504098700_bib17","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1038\/s41375-018-0135-8","article-title":"Phase 1\/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms","volume":"32","author":"Halpern","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"2024122319504098700_bib18","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.3324\/haematol.2018.204792","article-title":"Phase I\/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed\/refractory acute myeloid leukemia and other high-grade myeloid neoplasms","volume":"104","author":"Halpern","year":"2019","journal-title":"Haematologica"},{"issue":"6","key":"2024122319504098700_bib19","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2024122319504098700_bib20","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A\u00a0new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J\u00a0Chronic Dis"},{"issue":"8","key":"2024122319504098700_bib21","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1097\/00003246-198608000-00027","article-title":"APACHE II--a severity of disease classification system","volume":"14","author":"LeGall","year":"1986","journal-title":"Crit Care Med"},{"issue":"7","key":"2024122319504098700_bib22","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/BF01709751","article-title":"The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction\/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine","volume":"22","author":"Vincent","year":"1996","journal-title":"Intensive Care Med"},{"issue":"6","key":"2024122319504098700_bib23","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/ejh.13500","article-title":"Febrile neutropenia in patients with acute myeloid leukemia: Outcome in relation to qSOFA score, C-reactive protein, and blood culture findings","volume":"105","author":"Lappalainen","year":"2020","journal-title":"Eur J Haematol"},{"issue":"14","key":"2024122319504098700_bib24","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1001\/jama.286.14.1754","article-title":"Serial evaluation of the SOFA score to predict outcome in critically ill patients","volume":"286","author":"Ferreira","year":"2001","journal-title":"JAMA"},{"issue":"6","key":"2024122319504098700_bib25","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1136\/archdischild-2019-318548","article-title":"Height of fever and invasive bacterial infection","volume":"106","author":"Michelson","year":"2021","journal-title":"Arch Dis Child"},{"key":"2024122319504098700_bib26","doi-asserted-by":"crossref","first-page":"100394","DOI":"10.1016\/j.eclinm.2020.100394","article-title":"Re-evaluating and recalibrating predictors of bacterial infection in children with cancer and febrile neutropenia","volume":"23","author":"Haeusler","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"1","key":"2024122319504098700_bib27","doi-asserted-by":"crossref","first-page":"7429","DOI":"10.1038\/s41598-022-11576-z","article-title":"A\u00a0prediction model for bacteremia and transfer to intensive care in pediatric and adolescent cancer patients with febrile neutropenia","volume":"12","author":"Alali","year":"2022","journal-title":"Sci Rep"},{"issue":"suppl 16","key":"2024122319504098700_bib28","doi-asserted-by":"crossref","first-page":"e13626","DOI":"10.1200\/JCO.2023.41.16_suppl.e13626","article-title":"Early detection of CRS after CAR-T therapy using wearable monitoring devices: preliminary results in relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Rajeeve","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2024122319504098700_bib29","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/ejh.14264","article-title":"Novel biomarkers to identify complicated course of febrile neutropenia in hematological patients receiving intensive chemotherapy","volume":"113","author":"Jantunen","year":"2024","journal-title":"Eur J Haematol"},{"issue":"1","key":"2024122319504098700_bib30","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1080\/10428194.2021.1984451","article-title":"Comparative analysis of infectious complications with outpatient vs. inpatient care for adults with high-risk myeloid neoplasm receiving intensive induction chemotherapy","volume":"63","author":"Halpern","year":"2022","journal-title":"Leuk Lymphoma"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/24\/6161\/2345249\/blooda_adv-2024-014291-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/24\/6161\/2345249\/blooda_adv-2024-014291-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T14:50:53Z","timestamp":1734965453000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/24\/6161\/518082\/Identification-of-factors-predicting-low-risk"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,11]]},"references-count":30,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2024,12,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014291","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,11]]}}}